Catalyst Pharmaceuticals (CPRX) Other Non-Current Liabilities (2010 - 2026)

Catalyst Pharmaceuticals has reported Other Non-Current Liabilities for 15 years, with the latest figure at $280000.0 in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities rose 8.11% year-over-year to $280000.0; the trailing twelve-month figure through Mar 2026 stood at $280000.0 (up 8.11% YoY), and the FY2025 full-year result was $209000.0, down 33.65% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $280000.0, up from $209000.0 in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $14.7 million in Q3 2022, with the low at $161000.0 in Q3 2025.
• Historically, Other Non-Current Liabilities has averaged $4.7 million across 5 years, with a median of $2.6 million in 2024.
• Annual changes were most pronounced in 2025 — Other Non-Current Liabilities plunged 94.22% — and 2026, when it advanced 8.11%.
• Catalyst Pharmaceuticals' Other Non-Current Liabilities stood at $14.1 million in 2022, then slumped by 78.8% to $3.0 million in 2023, then sank by 89.44% to $315000.0 in 2024, then slumped by 33.65% to $209000.0 in 2025, then jumped by 33.97% to $280000.0 in 2026.
• The last three Other Non-Current Liabilities figures came in at $280000.0 (Q1 2026), $209000.0 (Q4 2025), and $161000.0 (Q3 2025), per Business Quant data.